Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Markel (MKL) first-quarter results reflect improved earned premiums and increased net investment income.